Rheumatology

Research

Research in Peer-Reviewed Journals

  1. Biologic therapy for rheumatoid arthritis in developing countries--a place for non-TNF inhibitors as first-line treatment?Tikly M, Hodkinson B, Dheda K.Rheumatology (Oxford). 2015 Feb;54(2):208-9
  2. Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index.Hodkinson B, Musenge E, Tikly M.Rheumatology (Oxford). 2015 Jun;54(6):1033-8.
  3. Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.Ally MM, Hodkinson B, Meyer PW, Musenge E, Tintinger GR, Tikly M, Anderson R.BMC Musculoskelet Disord. 2015 May 29;16:130.
  4. DNA methylation similarities in genes of black South Africans with systemic lupus erythematosus and systemic sclerosis. Matatiele P, Tikly M, Tarr G, Gulumian M. J Biomed Sci. 2015 May 20;22:34.
  5. Habitual Physical Activity, Sedentary Behaviour and Bone Health in Rheumatoid Arthritis. Prioreschi A, Makda MA, Tikly M, McVeigh JA. Int J Sports Med. 2015 Nov;36(12):1021-6.
  6. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Maurer B, Graf N, Michel BA, Müller-Ladner U, Czirják L, Denton CP, Tyndall A, Metzig C, Lanius V, Khanna D, Distler O; EUSTAR co-authors. Ann Rheum Dis. 2015 Jun;74(6):1124-31.
  7. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Hachulla E, Clerson P, Airò P, Cuomo G, Allanore Y, Caramaschi P, Rosato E, Carreira PE, Riccieri V, Sarraco M, Denton CP, Riemekasten G, Pozzi MR, Zeni S, Mihai CM, Ullman S, Distler O, Rednic S, Smith V, Walker UA, Matucci-Cerinic M, Müller-Ladner U, Launay D; EUSTAR co-workers. Rheumatology (Oxford). 2015 Jul;54(7):1262-9.
  8. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database.
  9. Wirz EG, Jaeger VK, Allanore Y, Riemekasten G, Hachulla E, Distler O, Airò P, Carreira PE, Tikly M, Vettori S, Balbir Gurman A, Damjanov N, Müller-Ladner U, Distler J, Li M, Häusermann P, Walker UA; EUSTAR coauthors. Ann Rheum Dis. 2015 Jul 31. pii: annrheumdis-2015-207271.
  10. Evidence-based treatment of systemic lupus erythematosus and its complications Hodkinson B, Makda MA. South African Medical Journal 2015;105(12):1075. DOI:10.7196/SAMJ.2015.v105i12.10221
  11. The Framingham Score and the Systematic Coronary Risk Evaluation at Low Cutoff Values Are Useful Surrogate Markers of High-risk Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. Dessein PH, Corrales A, Lopez-Mejias R, Solomon A, Woodiwiss AJ, Llorca J, Norton GR, Genre F, Blanco R, Pina, Gonzalez-Juanatey C, Tsang L, Gonzalez-Gay MA. J Rheumatol. 2016 Jan 15.
  12. Effect of human immunodeficiency virus infection on disease activity in rheumatoid arthritis: a retrospective study in South Africans. Tarr G, Makda M, Musenge E, Tikly M. J Rheumatol. 2014 Aug;41(8):1645-9.
  13. Immunochip identifies novel, and replicates known, genetic risk loci for rheumatoid arthritis in black South Africans. Govind N, Choudhury A, Hodkinson B, Ickinger C, Frost J, Lee A, Gregersen PK, Reynolds RJ, Bridges SL Jr, Hazelhurst S, Ramsay M, Tikly M. Mol Med. 2014 Aug 14;20:341-9.
  14. Spondyloarthritis in sub-Saharan Africa. Tikly M, Njobvu P, McGill P. Curr Rheumatol Rep. 2014. Jun;16(6):421.
  15. A prospective study of anti-tumor necrosis factor therapy in South African rheumatoid arthritis patients. Pettipher C, Rudolph R, Musenge E, Tikly M. Int J Rheum Dis. 2014 Feb 12.
  16. Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study. Faller G, Mistry BJ, Tikly M. Pediatr Rheumatol Online J. 2014 Jan 7;12:2.
  17. A three month controlled intervention of intermittent whole body vibration designed to improve functional ability and attenuate bone loss in patients with rheumatoid arthritis. Prioreschi A, Tikly M, McVeigh JA. BMC Musculoskelet Disord. 2014 Nov 29;15:403.
  18. Rheumatoid arthritis in the developing world: stepping up to the challenge. Hodkinson B, Tikly M, Adebajo A. Clin Rheumatol. 2014 Sep;33(9):1195-6. doi: 10.1007/s10067-014-2690-3. Epub 2014 Jun 4.
  19. Changes in physical activity measured by accelerometry following initiation of DMARD therapy in rheumatoid arthritis. Prioreschi A, Hodkinson B, Tikly M, McVeigh JA. Rheumatology (Oxford). 2014 May;53(5):923-6.
  20. Age impacts on the independent relationships of leptin with cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with rheumatoid arthritis: a cross-sectional study. Dessein PH, Norton GR, Woodiwiss AJ, Tsang L, Solomon A. Rheumatol Int. 2014 Mar;34(3):329-39.
  21. Cardiovascular disease risk amongst African black patients with rheumatoid arthritis: the need for population specific stratification. Solomon A, Tsang L, Woodiwiss AJ, Millen AM, Norton GR, Dessein PH. Biomed Res Int. 2014;2014:826095.
  22. Adiponectin and atherosclerosis in rheumatoid arthritis.Dessein PH, Tsang L, Solomon A, Woodiwiss AJ, Millen AM, Norton GR.Mediators Inflamm. 2014;2014:358949.